Gryphon-Backed Metagenics Acquires UK Probiotic Brand Symprove

January 23, 2026

Gryphon Investors-backed Metagenics has acquired Symprove, a UK-based probiotic brand, from bd-capital. The deal — terms undisclosed — was completed alongside a strategic debt recapitalization to provide Metagenics with additional capital for organic investment and future M&A; Symprove will continue to be led by CEO Will Bowler.

Buyers
Metagenics, Gryphon Investors
Targets
Symprove
Sellers
bd-capital
Platforms
Metagenics
Location
United Kingdom
Transaction Type
Addon

Explore More

Related Acquisitions

Track M&A activity that matters to you

Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.